- November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
- August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
- July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
- May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
- March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD
More posters
|
May 3, 2011 Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
Joan P. Blonder, Sarah C. Mutka, Dan Drolet, Bassam Damaj, Dianne Spicer, Vince Russell, Xicheng Sun, Gary J. Rosenthal, Charles Scoggin
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease often associated with cigarette smoking and characterized by progressive airflow limitation and lung damage.
In the lung, endogenous S-nitrosothiols (SNOs) including S-nitrosoglutathione (GSNO) mediate nitric oxide (NO)-based signaling, inflammatory status, and smooth muscle function. S-nitrosoglutathione reductase (GSNOR) inhibition represents a novel approach to treating COPD via restoring GSNO and GSNO-mediated anti-inflammatory and bronchodilatory activities.
The efficacy of small molecule inhibitors of GSNOR was evaluated in two murine models of COPD, a porcine pancreatic elastase (PPE) instillation model and a sub-chronic tobacco smoke (TS) inhalation model. More…poster PDF(440Kb)
Comments are closed.
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
